Vardenafil: A new oral treatment for erectile dysfunction

International Journal of Clinical Practice

Volumn 58, Issue 8, 2004, Pages 801-806

  Eardley, Ian ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitor; Vardenafil

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALUMINUM HYDROXIDE; ANTIHYPERTENSIVE AGENT; CARDIOVASCULAR AGENT; CIMETIDINE; CYCLIC GMP; ERYTHROMYCIN; KETOCONAZOLE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RANITIDINE; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

ARTICLE; BACKACHE; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EUROPE; FIRST PASS EFFECT; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RHINITIS; SKIN MANIFESTATION; UNITED STATES;

CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 4544340338     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00213.x     Document Type: Article

References (20)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
2. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6.
3. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational men's attitudes to life events and sexuality (MALES) Study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004; 20 (5): 607-17.
4. Saenz de Tejada I, Angulo J, Cuevas P et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-90.
5. Koltz T, Sachse R, Heidrich A et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19 (1): 32-9.
6. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43 (3): 260-7.
7. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53 (Suppl. 1): 5S-12S.
8. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. Dose normalised pharmacokinetics of Tadalafil (IC351) administered as a single dose to healthy volunteers. Int J Impot Res; 13 (Suppl. 4): [Abstract 120].
9. Klotz T, Bauer RJ, Wensing G. Effect of renal impairment on the single dose pharmacokinetics of vardenafil 20 mg, selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy 2002; 22: 418.
10. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23 (6): 763-71.
11. Porst H, Rosen R, Padma-Nathan H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13 (4): 192-9.
12. Hatzichristou D, Montorisi F, Taylor T. Efficacy of vardenafil in a flexible dose regimen: A placebo controlled trial. J Androl 2003; (Supplement): 48.
13. Padma-Nathan H, Montorsi F, Giuliano F et al for the North American and European vardenafil study group. Vardenafil restores erectile function to normal range in men with erectile dysfunction. Urology [in press].
14. Montorsi F, Hellstrom WJG, Valiquette L, Eardley I, Homering M, Bandel TJ. Reliable efficacy over time of vardenafil, a highly selective PDE5 inhibitor in men with erectile dysfunction: A retrospective analysis of two pivotal Phase III studies. Prog Urol 2003; 13 (Suppl. 2): 31. [Abstract 98].
15. Stief C, Porst H, Saenz de Tejada I, Ulbrich E. Sustained efficacy and tolerability of vardenafil over two years in men with erectile dysfunction. Prog Urol 2003; 13 (Suppl. 2): 31. [Abstract 100].
16. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T, Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26 (3): 777-83.
17. Brock G, Nehra A, Lipshultz LI et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170 (4 Part 1): 1278-83.
18. Padma Nathan H, Kaufman J, Taylor T. Earliest time of onset of erections with vardenafil determined in an at-home setting. J Androl 2003; (Supplement): 48.
19. Kloner R, Mohan P, Norenberg C et al. Cardiovascular safety of vardenafil a potent highly selective PDE5 inhibitor in patients with erectile dysfunction: an analysis of 5 placebo controlled trials. Pharmacotherapy 2002; 22: 1371.
20. Thadani U, Smith W, Nash S et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40 (11): 2006-12.